FIGURE 10.

Correlations between cell risk score and IC50 for different drugs. The correlation analysis between RBP‐related signature‐based risk score and IC50 of (A) Dexrazoxane, (B) PLX‐4720, (C) Okadaic acid, (D) Pluripotin, (E) Nelarabine, (F) Sapacitabine, (G) Vemurafenib, (H) PLX‐8394, (I) 8‐Chloro‐adenosine, (J) Oxaliplatin, (K) AM‐5992, (L) ARQ‐680, (M) ST‐3595, (N) IDH‐C227, (O) Encorafenib, (P) Palbociclib, (Q) LY‐3009120, (R) P‐529, (S) MLN‐7243. Spearman rank correlation test was implemented to estimate the correlation between risk score and IC50 of each drug. p <  0.05 was considered as statistically significant